Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tarsier Pharma Receives FDA Agreement for Tarsier-04 Phase 3 Trial of TRS01
Details : TRS01 (dazdotuftide) is a first-in-class NF-κB signaling pathway inhibitor, which is under phase 3 clinical development for the treatment of non-infectious uveitis including uveitic glaucoma.
Brand Name : TRS01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 16, 2024
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tarsier Pharma Announces Successful Type C Meeting with FDA for TRS01 in Noninfectious Uveitis
Details : TRS01 (dazdotuftide) is a bio-inspired novel proprietary technology platform, based on a New Chemical Entity (NCE) with a disruptive mechanism of action that modulate macrophages from inflammatory macrophages (M1) to IL-10 secreting ant-inflammatory macr...
Brand Name : TRS01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 13, 2023
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TRS01 (dazdotuftide) is a bio-inspired novel proprietary technology platform, based on a New Chemical Entity (NCE) with a disruptive mechanism of action that modulate macrophages from inflammatory macrophages (M1) to IL-10 secreting ant-inflammatory macr...
Brand Name : TRS01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 23, 2023
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma – that is considered an end-stage condition of uveitis.
Brand Name : TRS01
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 08, 2022
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma.
Brand Name : TRS01
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
September 22, 2021
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Tarsier Pharma Raises Capital to Execute Phase-3 Clinical Trial
Details : Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regulatory approvals to execute phase 3 for TRS01 and has recruited leading uveitis experts as principal investigators.
Brand Name : TRS01
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
August 24, 2021
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : TRS01,Adapalene
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company received important feedback on its trial design and program for its TRS01 Phase 3 program in uveitis, including feedback on its nonclinical and CMC plans supporting submission of a New Drug Application (NDA) in the U.S.
Brand Name : TRS01
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
December 17, 2020
Lead Product(s) : TRS01,Adapalene
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tarsius Pharma Achieves Positive Results In Proof Of Concept Study For TRS01 Targeting Uveitis
Details : Results showed a statistically significant improvement in the signs and symptoms of the disease, with the TRS01 high-dose usage being superior to low-dose in a few important measures.
Brand Name : TRS01
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
October 05, 2020
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TRS01 is a Potential topical immune-modulator agent with a novel mechanism of action for treatment of ocular inflammation. This phase I/II trial is a dose ranging trial to evaluate the safety and efficacy of TRS01 in patients with anterior non-infectious...
Brand Name : TRS01
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
June 22, 2020
Lead Product(s) : TRS01
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?